Synaptogenix (NASDAQ:TAOX) Lowered to Sell Rating by Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Synaptogenix has an average rating of “Sell”.

Synaptogenix Trading Down 7.6%

Shares of NASDAQ:TAOX opened at $4.27 on Friday. The company’s 50-day moving average is $5.38. The stock has a market cap of $31.81 million, a P/E ratio of -0.21 and a beta of 1.98. Synaptogenix has a one year low of $1.84 and a one year high of $11.98.

Synaptogenix (NASDAQ:TAOX) last released its quarterly earnings results on Friday, November 14th. The company reported ($1.56) earnings per share for the quarter. The business had revenue of $2.41 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.